Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-01-09
2007-01-09
Qian, Celine (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100
Reexamination Certificate
active
10077583
ABSTRACT:
The present invention relates to a new polypeptide and the gene encoding therefore, said gene being regulated in cardiac tissue by the transcription factor MEF2C. This polypeptide, CHAMP (cardiac helicase activated by MEF2 protein), bears striking resemblance to a number of other helicase proteins and appears to play a role in RNA processing and transcriptional control in heart muscle. For example, CHAMP has been demonstrated to inhibit both hypertrophy of primary cardiomyocytes and proliferation of non-cardiac cells. Also disclosed are methods of using the gene and protein in drug screening and therapy, including, for example, use of the gene in gene therapy to treat cardiovascular disease.
REFERENCES:
Accession No. HSM801339, Feb. 18, 2000.
Accession No. AF285604, Apr. 12, 2001.
Acession No. AX247728, Sep. 28, 2001.
Bork (Genome Research, 10:398-400, 2000).
Smith et al (Nature Biotechnology 15:1222-1223, 1997).
Brenner (TIG 15:132-133, 1999).
Broun et al. (Science 282:1315-1317, 1998).
Van de Loo et al. (Proc. Natl. Acad. Sci. 92:6743-6747, 1995).
Sigmund, C.D. 2000. Arterioscler Thromb Vasc Biol.20:1425-1429.
Wall, R.J. 1996. Theriogenology 45:57-68.
Verma et al. (1997, Nature, vol. 389, pp. 239-242).
GENEMBL Database Accession No. AL133068.
GENEMBL Database Accession No. AW552067.
Black and Olson, “Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins,”Annual Rev. Cell Dev. Biol.,14:167-196, 1998.
Chen, et al., “Evidence for regulation of transcription and replication of the human neurotropic virus JCV genome by the human S9mu)bp-2 protein in glial cells,”Gene, 185:55-62, 1997.
Cui, et al., “Identification and characterization of genes that are required for the accelerated degradation of mRNAs containing a premature translational termination codon,”Genes Devel.,9:423-436, 1995.
Czaplinski, et al., “Purification and characterization of the Upf1 protein: a factor involved in translation and mRNA degradation,”RNA, 1:610-623, 1995.
De la Crus, et al., “Undwinding RNA inSaccharomyces cerevisiae, DEAD-box proteins and related families,”Trends in Biochem. Sciences, 24:192-198, 1999.
DeMarini, et al., “SEN1, a positive effector of tRNA-splicing endonuclease inSaccharomyces cerevisiae,”Molecular Cellular Biol.,12:2154-2164, 1992.
Edmondson, et al., “Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis,”Development, 120:1251-1263, 1994.
Firulli, et al., “Heart and extra-embryonic mesodermal defects in mouse embryos lacking the bHLH transcription factor Hand1,”Nature Gene.,18:266-270, 1998.
Frey et al., “Calsarcins, a novel family of sarcomeric calcineurin-binding proteins,”Proc. Nat'l Acad. Sci. USA,97:14632-14637, 2000.
Gulley, et al., “Translocations of 11q13 in mantle cell lymphoma fail to disrupt the S mu bp-2 gene,”Hematopathology Molecular Hematology, 11:1-11, 1997.
Kim, et al., “The sen1(+) gene ofSchizosaccharomyces pombe, a homologue of budding yeast SEN1, encodes an RNA and DNA helicase,”Biochemistry, 38:14697-14710, 1999.
Kuisk, et al., “A single MEF2 site governs desmin transcription in both heart and skeletal muscle during mouse embryogenesis,”Developmental Biology, 174:1-13, 1996.
Leeds, et al., “The product of the yeast UPF1 gene is required for rapid turnover of mRNAs containing a premature translational termination codon,”Genes Development, 5:2303-2314, 1991.
Lelivelt and Culbertson, “Yeast Upf proteins required for RNA surveillance affect global expression of the eyast transcriptome,”Molecular Cellular Biology,19:6710-6719, 1999.
Lin, et al., “Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C,”Science, 276;1404-1407, 1997.
Liu and Olson, “Suppression of proliferation and cariomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase,”Proc. Natl. Acad. USA,99:2043-2048, 2002.
Liu, et al., “CHAMP, a novel cardiac-specific helicase regulated by MEF2C,”Dev. Biol.,234:497-509, 2001.
Nakagawa, et al., “HRT1, HRT2, and HRT3: a new subclass of bHLH transcription factors marking specific cardiac, somitic, and pharyngeal arch segment,”Develop. Biol.,216:72-84, 1999.
Nakajima, et al., “RNA helicase A mediates association of CBP with RNA polymerase II,”Cell, 90:1107-1112, 1997.
Nicol, et al., “Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy,” EMBO J., 20:2757-2767, 2001.
Nozato et al., “Overexpression of cdk inhibitor p16INK4aby adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy,”J. Mol. Cell. Cardiol.,33:1493-1504, 2001.
Ross, et al., “An HF-1a/HF-1b/MEF-2 combinatorial element confers cardiac ventricular specificity and established an anterior-posterior gradient of expression,”Development, 122:1799-1809, 1996.
Sebastiani, et al., “Localization of the Catf1 transcription factor gene to mouse chromosome 19,”Mammalian Genome, 6:147-148, 1995.
Siomi and Dreyfuss, “RNA-binding proteins as regulators of gene expression,”Curr. Opin. Genet. Dev.,7:345-353, 1997.
Weng, et al., “Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein,”Molecular Cellular Biol.,16:5477-5490, 1996.
Zhang, et al., “Sμbp-2 represses the Epstein-Barr virus lytic switch promoter,”Virology,255:160-170, 1999.
Liu Zhi-Ping
Olson Eric
Fulbright & Jaworski
Qian Celine
LandOfFree
CHAMP—a novel cardiac helicase-like factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CHAMP—a novel cardiac helicase-like factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CHAMP—a novel cardiac helicase-like factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816548